DXCM Dexcom Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DXCM

Price (delayed)

$137.87

Market cap

$53.15B

P/E Ratio

98.48

Dividend/share

N/A

EPS

$1.4

Enterprise value

$55.12B

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in ...

Highlights
Dexcom's net income has soared by 59% YoY and by 44% from the previous quarter
The EPS has soared by 59% YoY and by 43% QoQ
The debt has increased by 22% YoY but it has decreased by 4.7% from the previous quarter
The company's equity fell by 9% QoQ and by 3% YoY
The gross margin has declined by 2.3% year-on-year
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.dexcom.com/
Peers: EW WST BDX TNDM

Key stats

What are the main financial stats of DXCM
Market
Shares outstanding
385.52M
Market cap
$53.15B
Enterprise value
$55.12B
Valuations
Price to earnings (P/E)
98.48
Price to book (P/B)
25.75
Price to sales (P/S)
14.69
EV/EBIT
75.43
EV/EBITDA
60.13
EV/Sales
15.22
Earnings
Revenue
$3.62B
EBIT
$730.7M
EBITDA
$916.7M
Free cash flow
$511.9M
Per share
EPS
$1.4
Free cash flow per share
$1.33
Book value per share
$5.35
Revenue per share
$9.38
TBVPS
$15.82
Balance sheet
Total assets
$6.26B
Total liabilities
$4.2B
Debt
$2.54B
Equity
$2.07B
Working capital
$2.87B
Liquidity
Debt to equity
1.23
Current ratio
2.84
Quick ratio
2.38
Net debt/EBITDA
2.15
Margins
EBITDA margin
25.3%
Gross margin
63.2%
Net margin
14.9%
Operating margin
16.5%
Efficiency
Return on assets
8.6%
Return on equity
25%
Return on invested capital
11.7%
Return on capital employed
15.5%
Return on sales
20.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DXCM stock price

How has the Dexcom stock price performed over time
Intraday
2.89%
1 week
3%
1 month
3.52%
1 year
11.34%
YTD
11.1%
QTD
-0.6%

Financial performance

How have Dexcom's revenue and profit performed over time
Revenue
$3.62B
Gross profit
$2.29B
Operating income
$597.7M
Net income
$541.5M
Gross margin
63.2%
Net margin
14.9%
Dexcom's net income has soared by 59% YoY and by 44% from the previous quarter
DXCM's operating income has surged by 53% year-on-year and by 18% since the previous quarter
The net margin has increased by 34% from the previous quarter and by 27% YoY
Dexcom's revenue has increased by 24% YoY and by 6% from the previous quarter

Growth

What is Dexcom's growth rate over time

Valuation

What is Dexcom stock price valuation
DXCM P/E details
P/E
98.48
P/B
25.75
P/S
14.69
EV/EBIT
75.43
EV/EBITDA
60.13
EV/Sales
15.22
The EPS has soared by 59% YoY and by 43% QoQ
The stock's price to earnings (P/E) is 26% less than its 5-year quarterly average of 133.0 and 17% less than its last 4 quarters average of 118.7
DXCM's P/B is 24% above its last 4 quarters average of 20.7 and 20% above its 5-year quarterly average of 21.4
The company's equity fell by 9% QoQ and by 3% YoY
Dexcom's revenue has increased by 24% YoY and by 6% from the previous quarter
The stock's price to sales (P/S) is 8% less than its 5-year quarterly average of 16.0 but 8% more than its last 4 quarters average of 13.6

Efficiency

How efficient is Dexcom business performance
The ROE has soared by 54% year-on-year and by 45% since the previous quarter
DXCM's return on invested capital has surged by 54% year-on-year and by 9% since the previous quarter
The ROS rose by 43% YoY and by 12% QoQ
Dexcom's ROA has increased by 39% from the previous quarter and by 30% YoY

Dividends

What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DXCM.

Financial health

How did Dexcom financials performed over time
The company's total assets is 49% higher than its total liabilities
Dexcom's current ratio has increased by 43% YoY
The quick ratio has grown by 38% year-on-year
The debt is 23% more than the equity
DXCM's debt to equity is up by 26% YoY and by 5% QoQ
The debt has increased by 22% YoY but it has decreased by 4.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.